Over the past decade, the superbug Clostrodium difficile (C. diff) has been on the rise in hospitals throughout the United States and England. The trend has many health experts concerned, as most strains of the bacteria are resistant to antibiotics, making them very difficult to treat and potentially deadly.
But now, researchers from the University of Leicester in England may have discovered a more potent, and seemingly unlikely, treatment for these highly infectious bacteria: viruses.
Through work funded by the British Medical Research Council (MRC), researchers have shown that a group of naturally occurring bacteria-eating viruses – known as phages – effectively target and destroy C. diff bacteria in cell cultures.
According to lead investigator Dr. Martha Clokie, while phages have often been used to target other forms of bacteria, they have yet to be used to target C. diff.
“(Researchers) haven’t really found C. diff phages before, partly because they looked in the wrong places,” Clokie, from the University of Leicester’s department of infection, immunity and inflammation, told FoxNews.com. “We know C. diff to be a gut pathogen, causing huge problems in hospital settings, but it also has a strong presence in environmental settings… And wherever you find bacteria in a natural environment, you will almost always find viruses (that target them).”
With this theory in mind, Clokie and her team searched environmental areas where C. diff is known to exist, such as in soil, rivers and estuaries. Together, they managed to isolate around 40 different viruses associated with the bacteria – the largest known set of C. diff phages ever collected.
The researchers then tested the phages on clinically relevant strains of C. diff bacteria in cell cultures. Ultimately, they were able to identify a mixture of seven viruses that effectively destroyed the most problematic strains of the bacteria.
“When we add the viruses to the bacteria, the bacteria die in petri dishes,” Clokie said. “We can also grow gut cells on plates, infect our gut cells with C. diff, and show that adding these viruses gets rid of the C. diff.”
Given the success of their research, Clokie and her team have partnered with the AmpliPhi Biosciences Corporation, a U.S.-based biopharmaceutical company that specializes in the development of phage-based treatments for bacterial infections. Through their partnership, they have patented Clokie’s virus mixture, hoping to develop it further into a viable treatment option.
“It’d be like an oral pill – a little capsule of viruses,” Clokie explained. “It’d allow viruses to pass through the stomach, degrade at that point and access C. diff where it needs to. We’re at an exciting stage for this; we’re not quite there yet, but we’re in an exciting place.”
A phage-therapy such as this one is desperately needed in both the United States and England. While hospital acquired infections (HAIs) have declined in the United States in recent years, C. diff still remains at historically high levels. According to the Centers for Disease Control and Prevention, the superbug is linked with 14,000 American deaths each year. C. diff is also extremely difficult to treat as many of the clinically significant strains of the bacteria are naturally resistant to antibiotics.
Additionally, the people most at risk for C. diff infection – which often involves severe dehydration and diarrhea – are sick or elderly patients who have recently been treated with antibiotics in a hospital or other medical setting.
Although antibiotics are valuable for their ability to destroy harmful bacteria in the body, they also effectively kill the body’s “good” bacteria, which help protect against unwanted infection. As a result, this makes patients more susceptible to contracting C. diff from contaminated surfaces or the unwashed hands of health care workers.
Clokie said one of the great things about her team’s phage mixture is that it bypasses this very significant problem.
“The viruses are so specific (to C. diff) that they won’t even kill other bacterial species,” Clokie said. “Antibiotics kill other bacteria you actually need, but these viruses are so specific that they just take out C. diff. They can’t even recognize human cells and use them as hosts.”
With further funding from AmpliPhi, Clokie is working on having a fully developed phage mixture ready to go into phase 1 and phase 2 clinical trials relatively soon. She believes that a shift towards phage-based therapies could help eliminate the negative impact antibiotics have had on increasing HAIs and spurring antibiotic resistance.
“It would really allow doctors to have another way of treating patients,” Clokie said. “As soon as people get a little sick with C. diff, you could give them this virus mixture. We hope to lower patient death rate and reduce their stays in hospital, so we would be reducing the health care burden in general.”